Braveheart Bio (NASDAQ:BRVE) Trading Up 8% – Should You Buy?

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE) rose 8% during trading on Tuesday . The stock traded as high as $28.13 and last traded at $28.87. Approximately 36,977 shares were traded during trading, a decline of 89% from the average session volume of 342,337 shares. The stock had previously closed at $26.74.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BRVE. Zacks Research raised shares of Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. Cantor Fitzgerald initiated coverage on Braveheart Bio in a research report on Monday, August 31st. They issued an “overweight” rating and a $40.00 target price on the stock. Stifel Nicolaus started coverage on Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $45.00 target price on the stock. The Goldman Sachs Group started coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $48.00 price target for the company. Finally, TD Cowen began coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Braveheart Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Braveheart Bio Stock Up 6.1%

Insiders Place Their Bets

In related news, major shareholder Growth Opportunities F. Forbion acquired 1,680,000 shares of the stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $30,240,000.00. Following the purchase, the insider directly owned 10,185,478 shares in the company, valued at approximately $183,338,604. The trade was a 19.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Erez Chimovits acquired 1,940,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the acquisition, the director directly owned 11,901,826 shares in the company, valued at approximately $214,232,868. This represents a 19.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 8,751,942 shares of company stock valued at $157,534,956 in the last quarter.

Braveheart Bio Company Profile

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.